The good news on the economic front has started to roll in once again, with the latest being China-based Oryx Biotech's announcement to invest $300 million to set up a plasma fractionation plant in Bangladesh. The company yesterday inked the tripartite agreement with Summit Technopolis, a company of Summit Group, and the Bangladesh Hi-Tech Park Authority (BHTPA) for the